Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Solid Tumors 2Neoplasms 2Liposarcoma 2Urinary Bladder Neoplasms 1Solid Tumours 1Pancreatic Neoplasms 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Dermatofibrosarcoma 1Biliary Tract Neoplasms 1

Interventions

Trabectedin 4Doxorubicin 4toripalimab 2brigimadlin 2belinostat 2Fulvestrant 2Dexamethasone 2tanespimycin 1soblidotin 1siremadlin 1selinexor 1ridaforolimus 1ribociclib 1pembrolizumab 1olaratumab 1milademetan 1enzalutamide 1cemiplimab 1atezolizumab 1TTI-621 1Sugars 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Midazolam 1Letrozole 1Injections 1Immunotherapy 1Imatinib Mesylate 1Ifosfamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Liposarcoma × brigimadlin × Clear all
NCT05218499 2026-03-02

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 2/3 Completed
400 enrolled 15 charts
Sarcoma

Liposarcoma

NCT06058793 2026-01-09

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 3 Completed
138 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡